RU2495044C2 - Ингибиторы активности протеинтирозинкиназы - Google Patents
Ингибиторы активности протеинтирозинкиназы Download PDFInfo
- Publication number
- RU2495044C2 RU2495044C2 RU2010111729/04A RU2010111729A RU2495044C2 RU 2495044 C2 RU2495044 C2 RU 2495044C2 RU 2010111729/04 A RU2010111729/04 A RU 2010111729/04A RU 2010111729 A RU2010111729 A RU 2010111729A RU 2495044 C2 RU2495044 C2 RU 2495044C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- compound according
- compound
- independently selected
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title claims abstract 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title claims abstract 4
- 230000000694 effects Effects 0.000 title claims abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 229910005965 SO 2 Inorganic materials 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 C*=NC=*NC Chemical compound C*=NC=*NC 0.000 description 4
- QKDNWXDBCHIALI-UHFFFAOYSA-N CC(C1)CN=C1NC(NC(C(Cl)=C1)=CC=[IH]1Oc1ccnc2c1[s]c(-c1ccc(CNCCOC)cn1)c2)=O Chemical compound CC(C1)CN=C1NC(NC(C(Cl)=C1)=CC=[IH]1Oc1ccnc2c1[s]c(-c1ccc(CNCCOC)cn1)c2)=O QKDNWXDBCHIALI-UHFFFAOYSA-N 0.000 description 1
- BTAWMJIJKXEXFL-UHFFFAOYSA-N COCCNCc1ccc(-c2cc(nccc3Oc(c(F)c4)ccc4NC(Nc4cccnc4)O)c3[s]2)nc1 Chemical compound COCCNCc1ccc(-c2cc(nccc3Oc(c(F)c4)ccc4NC(Nc4cccnc4)O)c3[s]2)nc1 BTAWMJIJKXEXFL-UHFFFAOYSA-N 0.000 description 1
- XAIANZPOYOIMDB-UHFFFAOYSA-N COCCNCc1ccc(-c2cc(nccc3Oc(ccc(NC(NC4CC4)=O)c4)c4F)c3[s]2)nc1 Chemical compound COCCNCc1ccc(-c2cc(nccc3Oc(ccc(NC(NC4CC4)=O)c4)c4F)c3[s]2)nc1 XAIANZPOYOIMDB-UHFFFAOYSA-N 0.000 description 1
- ONKHQAHQKCNRHN-UHFFFAOYSA-N Cc1cc(NC(Nc(c(OC)c2)ccc2Oc2c3[s]c(-c4ccc(CNCCOC)cn4)cc3ncc2)=O)n[o]1 Chemical compound Cc1cc(NC(Nc(c(OC)c2)ccc2Oc2c3[s]c(-c4ccc(CNCCOC)cn4)cc3ncc2)=O)n[o]1 ONKHQAHQKCNRHN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96867307P | 2007-08-29 | 2007-08-29 | |
| US60/968,673 | 2007-08-29 | ||
| PCT/CA2008/001538 WO2009026717A1 (en) | 2007-08-29 | 2008-08-28 | Inhibitors of protein tyrosine kinase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010111729A RU2010111729A (ru) | 2011-10-10 |
| RU2495044C2 true RU2495044C2 (ru) | 2013-10-10 |
Family
ID=40386626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010111729/04A RU2495044C2 (ru) | 2007-08-29 | 2008-08-28 | Ингибиторы активности протеинтирозинкиназы |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8404846B2 (enExample) |
| EP (1) | EP2183254B1 (enExample) |
| JP (1) | JP5656634B2 (enExample) |
| KR (1) | KR101556269B1 (enExample) |
| CN (3) | CN109970759A (enExample) |
| AR (1) | AR068066A1 (enExample) |
| AU (1) | AU2008293038B2 (enExample) |
| BR (1) | BRPI0816064B8 (enExample) |
| CA (1) | CA2697795C (enExample) |
| DK (1) | DK2183254T3 (enExample) |
| ES (1) | ES2635131T3 (enExample) |
| IL (1) | IL204192A (enExample) |
| MX (1) | MX2010002427A (enExample) |
| MY (1) | MY156536A (enExample) |
| PL (1) | PL2183254T3 (enExample) |
| RU (1) | RU2495044C2 (enExample) |
| TW (1) | TWI571468B (enExample) |
| WO (1) | WO2009026717A1 (enExample) |
| ZA (1) | ZA201001512B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009109035A1 (en) * | 2008-03-05 | 2009-09-11 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
| CA2740746A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds comprising a spiro-ring and and methods of use |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| US8614234B2 (en) * | 2009-09-03 | 2013-12-24 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| PH12012502073A1 (en) * | 2010-04-16 | 2013-02-11 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| JP2013540759A (ja) * | 2010-09-27 | 2013-11-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| CN103391773A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103626761B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| KR102595599B1 (ko) | 2014-12-02 | 2023-11-02 | 이그니타, 인코포레이티드 | 신경모세포종의 치료를 위한 병용 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
| CN108697661A (zh) | 2015-12-18 | 2018-10-23 | 亚尼塔公司 | 用于治疗癌症的组合 |
| CN108530464B (zh) * | 2017-03-02 | 2020-10-27 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂 |
| EP3654952A1 (en) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
| ES2980476T3 (es) | 2018-03-08 | 2024-10-01 | Wellmarker Bio Co Ltd | Derivados de tienopiridina y composición farmacéutica que los contiene |
| MX2020012567A (es) | 2018-05-23 | 2021-01-29 | Beigene Ltd | Anticuerpos anti-ox40 y metodos de uso. |
| CN109384799B (zh) * | 2018-11-12 | 2020-07-14 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物 |
| WO2021045279A1 (ko) | 2019-09-06 | 2021-03-11 | 웰마커바이오 주식회사 | 바이오마커 기반 치료용 조성물 |
| EP4027999B1 (en) | 2019-09-10 | 2026-03-04 | Mirati Therapeutics, Inc. | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof |
| CN114728063B (zh) * | 2019-11-21 | 2024-06-14 | 百济神州有限公司 | 用抗ox40抗体和多重激酶抑制剂治疗癌症 |
| EP4089095A4 (en) * | 2020-01-07 | 2024-03-27 | Medshine Discovery Inc. | DEUTERATED THIENOPYRIDINE COMPOUND |
| EP4213844A4 (en) | 2020-09-17 | 2024-11-20 | Mirati Therapeutics, Inc. | POLYTHERAPIES |
| TW202302597A (zh) * | 2021-03-10 | 2023-01-16 | 美商米拉蒂醫療公司 | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 |
| WO2022240802A1 (en) | 2021-05-10 | 2022-11-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of sitravatinib salts and processes for preparation thereof |
| WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
| CN118846073B (zh) * | 2024-06-25 | 2026-01-30 | 深圳海王医药科技研究院有限公司 | 一种酪氨酸激酶抑制剂的新应用 |
| CN121281693B (zh) * | 2025-12-08 | 2026-04-03 | 中国石油大学(华东) | 一种构建稠油重组分平均分子结构的方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2571680A1 (en) * | 2004-06-28 | 2006-01-12 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| WO2006010264A1 (en) * | 2004-07-30 | 2006-02-02 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| WO2006104161A1 (ja) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | ｃ－Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体 |
| CA2605680A1 (en) * | 2005-04-27 | 2006-11-02 | Amgen Inc. | Substituted amide derivatives as protein kinase inhibitors |
| CA2611370A1 (en) * | 2005-05-20 | 2006-11-20 | Oscar Mario Saavedra | Inhibitors of vegf receptor and hgf receptor signaling |
| EA008255B1 (ru) * | 2002-06-14 | 2007-04-27 | Пфайзер Инк. | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения |
| US20070197537A1 (en) * | 2006-01-30 | 2007-08-23 | Blake James F | Heterobicyclic thiophene compounds and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019A (en) * | 1850-01-15 | Improvement in obstetrical supporters | ||
| US7000A (en) * | 1850-01-08 | Smut-machine | ||
| WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| DE60208364T2 (de) | 2001-04-27 | 2006-09-28 | Kirin Beer K.K. | Chinolinderivate mit einer azolylgruppe und chinazolinderivate |
| CA2454538A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| WO2003049685A2 (en) * | 2001-12-07 | 2003-06-19 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| EP1719762B1 (en) | 2004-02-27 | 2012-06-27 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| MXPA06010542A (es) * | 2004-03-15 | 2007-03-28 | Ptc Therapeutics Inc | Derivados de carbolina tetra-ciclica para la inhibicion de angiogenesis. |
| ES2473341T3 (es) | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
| TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| PL1889836T3 (pl) | 2005-08-24 | 2013-10-31 | Eisai R&D Man Co Ltd | Nowa pochodna pirydyny i pochodna pirymidyny (3) |
| MX2008011220A (es) | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
| WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| US20110053931A1 (en) | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| WO2008049855A2 (en) | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
| PH12012502073A1 (en) * | 2010-04-16 | 2013-02-11 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
-
2008
- 2008-08-28 EP EP08800252.2A patent/EP2183254B1/en active Active
- 2008-08-28 PL PL08800252T patent/PL2183254T3/pl unknown
- 2008-08-28 CN CN201910332646.2A patent/CN109970759A/zh active Pending
- 2008-08-28 JP JP2010522149A patent/JP5656634B2/ja active Active
- 2008-08-28 MY MYPI2010000797A patent/MY156536A/en unknown
- 2008-08-28 WO PCT/CA2008/001538 patent/WO2009026717A1/en not_active Ceased
- 2008-08-28 BR BRPI0816064A patent/BRPI0816064B8/pt active IP Right Grant
- 2008-08-28 DK DK08800252.2T patent/DK2183254T3/en active
- 2008-08-28 RU RU2010111729/04A patent/RU2495044C2/ru active
- 2008-08-28 MX MX2010002427A patent/MX2010002427A/es active IP Right Grant
- 2008-08-28 AU AU2008293038A patent/AU2008293038B2/en active Active
- 2008-08-28 CN CN201610143388.XA patent/CN105777776B/zh active Active
- 2008-08-28 CA CA2697795A patent/CA2697795C/en active Active
- 2008-08-28 ES ES08800252.2T patent/ES2635131T3/es active Active
- 2008-08-28 CN CN2008801139404A patent/CN101932586A/zh active Pending
- 2008-08-28 KR KR1020107006866A patent/KR101556269B1/ko active Active
- 2008-08-29 US US12/200,939 patent/US8404846B2/en active Active
- 2008-08-29 AR ARP080103775A patent/AR068066A1/es active IP Right Grant
- 2008-08-29 TW TW097133329A patent/TWI571468B/zh active
-
2010
- 2010-02-25 IL IL204192A patent/IL204192A/en active IP Right Grant
- 2010-03-02 ZA ZA2010/01512A patent/ZA201001512B/en unknown
-
2011
- 2011-12-30 US US13/341,604 patent/US8389541B2/en active Active
-
2013
- 2013-02-14 US US13/767,506 patent/US8846927B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008255B1 (ru) * | 2002-06-14 | 2007-04-27 | Пфайзер Инк. | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения |
| CA2571680A1 (en) * | 2004-06-28 | 2006-01-12 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| WO2006010264A1 (en) * | 2004-07-30 | 2006-02-02 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| WO2006104161A1 (ja) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | ｃ－Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体 |
| CA2605680A1 (en) * | 2005-04-27 | 2006-11-02 | Amgen Inc. | Substituted amide derivatives as protein kinase inhibitors |
| CA2611370A1 (en) * | 2005-05-20 | 2006-11-20 | Oscar Mario Saavedra | Inhibitors of vegf receptor and hgf receptor signaling |
| US20070197537A1 (en) * | 2006-01-30 | 2007-08-23 | Blake James F | Heterobicyclic thiophene compounds and methods of use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2405774C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| RU2342367C2 (ru) | Ненуклеозидные ингибиторы i обратной транскриптазы, предназначенные для лечения заболеваний, опосредованных вич | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| JP2010504346A5 (enExample) | ||
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| RU2010126056A (ru) | Органические соединения | |
| RU2006109004A (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
| BR112021026682A2 (pt) | Compostos e métodos para inibir eif4e | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| IS7982A (is) | Ný efnasambönd | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| RU2010116779A (ru) | Производное амида индазолакриловой кислоты | |
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| JP2021514399A5 (enExample) | ||
| UY28688A1 (es) | Derivados de amida | |
| RU2014131017A (ru) | Хиназолиноновые производные в качестве ингибиторов hcv | |
| RU2004130284A (ru) | Антипаразитарные производные артемизинина (эндопероксиды) | |
| RU2010137336A (ru) | Производное 3,8-диаминотетрагидрохинолина |